Abstract
The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.
Original language | English (US) |
---|---|
Pages (from-to) | 951-960 |
Number of pages | 10 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 10 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2012 |
Funding
This work is financially supported by the European project TECHNEAU and Agence de l’eau Seine— Normandie (AESN). Long and useful discussions we had with Pascal Roche, David Benanou and Karine Drouet are greatly appreciated.
ASJC Scopus subject areas
- Oncology